



State of the Art: Prerequisites, Prevention and Treatment of Neurodegenerative Diseases

Guest Editors:

Dr. Ekaterina Rudnitskaya

Federal Research Center Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Lavrentieva Ave. 10, 630090 Novosibirsk, Russia

Dr. Nataliya Kolosova

Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG SB RAS), 10 Lavrentyeva Ave., 630090 Novosibirsk, Russia

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editors

Progress in modern medicine leads to an increase in human lifespans. However, along with this advantage, it also leads to an increasing rate of age-related diseases. Among them, neurodegenerative disorders leading to the development of dementia seem to have the most burden on patients and caregivers. The hallmark of neurodegenerative disorders is their incurability; besides, most of them are difficult to diagnose and distinguish from one another, especially at early stages. Furthermore, some neurodegenerative disorders may last asymptotically for years and decades. Middle age is widely held as a critical period for the launch of pathological processes, but the question of when exactly neurodegeneration begins to develop and what contributes to its onset still remains open. The risk factors of consequent cognitive impairment later in life and accelerated brain aging could be formed already in the early postnatal period of life, during the completion of brain development. Thus, it determines the relevance of studies directed on investigations of risk factors, early diagnosis, prevention and treatment of neurodegenerative disorders.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)